[go: up one dir, main page]

IT1251544B - Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico - Google Patents

Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Info

Publication number
IT1251544B
IT1251544B ITMI911299A ITMI911299A IT1251544B IT 1251544 B IT1251544 B IT 1251544B IT MI911299 A ITMI911299 A IT MI911299A IT MI911299 A ITMI911299 A IT MI911299A IT 1251544 B IT1251544 B IT 1251544B
Authority
IT
Italy
Prior art keywords
derivative
therapy
pharmaceutical compositions
association
sleep disorders
Prior art date
Application number
ITMI911299A
Other languages
English (en)
Inventor
Gabriele Biella
Franco Fraschini
Bojidar Stankov
Original Assignee
Gabriele Biella
Franco Fraschini
Bojidar Stankov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gabriele Biella, Franco Fraschini, Bojidar Stankov filed Critical Gabriele Biella
Publication of ITMI911299A0 publication Critical patent/ITMI911299A0/it
Priority to ITMI911299A priority Critical patent/IT1251544B/it
Priority to AT92107865T priority patent/ATE142877T1/de
Priority to EP92107865A priority patent/EP0513702B1/en
Priority to EP95118386A priority patent/EP0713701B1/en
Priority to ES92107865T priority patent/ES2093735T3/es
Priority to DE69230046T priority patent/DE69230046T2/de
Priority to DK95118386T priority patent/DK0713701T3/da
Priority to DK92107865.5T priority patent/DK0513702T3/da
Priority to ES95118386T priority patent/ES2139132T3/es
Priority to DE69213814T priority patent/DE69213814T2/de
Priority to AT95118386T priority patent/ATE184792T1/de
Priority to JP4146983A priority patent/JPH05155769A/ja
Publication of ITMI911299A1 publication Critical patent/ITMI911299A1/it
Priority to US08/161,744 priority patent/US5430029A/en
Application granted granted Critical
Publication of IT1251544B publication Critical patent/IT1251544B/it
Priority to GR960403498T priority patent/GR3022060T3/el
Priority to GR990403294T priority patent/GR3032207T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invenzione si riferisce a nuove composizioni farmaceutiche attive nella terapia dei disturbi del sonno, comprendenti N-acetil-5-metossitriptamina (melatonina) o uno dei suoi derivati, preferibilmente 2-iodo-N-acetil-5-metossitriptamina (2-iodomelatonina) o 6-cloro-N-acetil-5-metossitriptamina (6-cloromelatonina), in dosi comprese fra 10 e 100 mg, preferibilmente comprese rispettivamente fra 20 e 80 mg, fra 10 e 20 mg e fra 10 e 40 mg, in associazione con un derivato benzodiazepinico in dosi comprese fra 0,1 e 25 mg.
ITMI911299A 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico IT1251544B (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
ES95118386T ES2139132T3 (es) 1991-05-13 1992-05-11 Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
AT95118386T ATE184792T1 (de) 1991-05-13 1992-05-11 2-bromomelatonin zur behandlung von schlafstörungen
EP95118386A EP0713701B1 (en) 1991-05-13 1992-05-11 2-Bromomelatonin in the therapy of sleep disorders
ES92107865T ES2093735T3 (es) 1991-05-13 1992-05-11 Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
DE69230046T DE69230046T2 (de) 1991-05-13 1992-05-11 2-Bromomelatonin zur Behandlung von Schlafstörungen
DK95118386T DK0713701T3 (da) 1991-05-13 1992-05-11 2-Brommelatonin til behandling af søvnforstyrrelser
DK92107865.5T DK0513702T3 (da) 1991-05-13 1992-05-11 Melatoninderivater til anvendelse til behandling af søvnlidelser og til præ-anæstetisk medicinering
AT92107865T ATE142877T1 (de) 1991-05-13 1992-05-11 Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
DE69213814T DE69213814T2 (de) 1991-05-13 1992-05-11 Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
EP92107865A EP0513702B1 (en) 1991-05-13 1992-05-11 Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
JP4146983A JPH05155769A (ja) 1991-05-13 1992-05-13 睡眠障害の治療に活性な製薬組成物
US08/161,744 US5430029A (en) 1991-05-13 1993-12-02 Pharmaceutical compositions active in the therapy of sleep disorders
GR960403498T GR3022060T3 (en) 1991-05-13 1996-12-17 Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
GR990403294T GR3032207T3 (en) 1991-05-13 1999-12-21 2-Bromomelatonin in the therapy of sleep disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Publications (3)

Publication Number Publication Date
ITMI911299A0 ITMI911299A0 (it) 1991-05-13
ITMI911299A1 ITMI911299A1 (it) 1992-11-13
IT1251544B true IT1251544B (it) 1995-05-17

Family

ID=11359886

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Country Status (9)

Country Link
US (1) US5430029A (it)
EP (2) EP0713701B1 (it)
JP (1) JPH05155769A (it)
AT (2) ATE184792T1 (it)
DE (2) DE69230046T2 (it)
DK (2) DK0713701T3 (it)
ES (2) ES2139132T3 (it)
GR (2) GR3022060T3 (it)
IT (1) IT1251544B (it)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0483077T3 (da) * 1990-09-28 1996-04-15 I F L O S A S Di Giorgio E Ald Fremgangsmåde til syntese af et kontraceptivt og menstruationscyklus-kontrollerende lægemiddel med onkostatiske, antikinetosiske, præventive og terapeutiske egenskaber til behandling af brysttumorer og melanomer
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IT1262912B (it) * 1992-12-30 1996-07-22 Impiego della melatonina nella terapia della sclerosi sistemica, della sarcoidosi ed altro
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
AU726758B2 (en) * 1993-11-18 2000-11-23 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
EP0754183A1 (fr) * 1994-04-07 1997-01-22 Cemaf Nouveaux derives de spiro[indole-pyrrolidine] agonistes melatoninergiques, leur procede de preparation et leur utilisation a titre de medicament
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
SK284521B6 (sk) * 1995-02-01 2005-05-05 Neurim Pharmaceuticals (1991) Ltd. Použitie melatonínu na prípravu farmaceutického prostriedku
CA2332521C (en) 1998-06-09 2009-02-10 Takeda Chemical Industries, Ltd. Pharmaceutical composition for treating or preventing sleep disorders
FR2787447B1 (fr) 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000045832A2 (en) * 1999-02-05 2000-08-10 The Victoria University Of Manchester Regulation of anaesthesia
US6552064B2 (en) * 2000-09-19 2003-04-22 University Of Iowa Research Foundation Use of melatonin for induction of general anesthesia
US6638966B2 (en) 2000-09-19 2003-10-28 University Of Iowa Research Foundation Use of melatonin analogues for induction of general anesthesia
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
DK1691811T3 (da) * 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
ES2337700T3 (es) 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
US8053462B2 (en) 2004-03-08 2011-11-08 Masanori Somei Indole derivative and application thereof
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20090105333A1 (en) * 2006-05-22 2009-04-23 Gunther Birznieks Melatonin agonist treatment
EP3620794A1 (en) 2012-01-26 2020-03-11 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
JP6144358B2 (ja) 2012-12-18 2017-06-07 ヴァンダ ファーマシューティカルズ インコーポレイテッド 概日リズム障害の治療
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
EP4478887A1 (en) * 2022-02-16 2024-12-25 La Pharma Tech Inc. Novel pharmaceutical compositions and methods for treatment of insomnia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
WO1989001472A1 (en) * 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues

Also Published As

Publication number Publication date
JPH05155769A (ja) 1993-06-22
EP0713701B1 (en) 1999-09-22
EP0513702A2 (en) 1992-11-19
GR3032207T3 (en) 2000-04-27
ITMI911299A1 (it) 1992-11-13
ITMI911299A0 (it) 1991-05-13
EP0713701A1 (en) 1996-05-29
ES2093735T3 (es) 1997-01-01
DE69213814T2 (de) 1997-04-03
DE69230046T2 (de) 2000-05-31
DK0713701T3 (da) 2000-04-03
DE69213814D1 (de) 1996-10-24
GR3022060T3 (en) 1997-03-31
EP0513702A3 (en) 1992-11-25
ATE184792T1 (de) 1999-10-15
ES2139132T3 (es) 2000-02-01
ATE142877T1 (de) 1996-10-15
EP0513702B1 (en) 1996-09-18
DE69230046D1 (de) 1999-10-28
DK0513702T3 (da) 1996-12-30
US5430029A (en) 1995-07-04

Similar Documents

Publication Publication Date Title
IT1251544B (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
ATE243196T1 (de) Piperidine und pyrrolidine
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ATE170075T1 (de) Antivirales arzneimittel enthaltend prostratin
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
ATE133680T1 (de) Oligosaccharidderivate und deren verwendung in heilmitteln
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
IL98199A (en) Pharmaceutical compositions containing a derivative of substituted l-valyl-l-prolinamide
NO922635L (no) Ny anvendelse av benzimidazolin-2-okso-1-karboksylsyrederivater
DK0615439T3 (da) Iburprofenholdigt retard-lægemiddel og dets anvendelse
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
GB9202993D0 (en) Novel pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use
IT1254544B (it) Derivato di l-verbenone e composizioni farmaceutiche che lo contengono
MX9701294A (es) Un medicamento que contiene un derivado de carnitina para el tratamiento de la arterioesclerosis cronica obliteradora.
IT1243368B (it) Uso del bendazac e dei suoi sali farmaceuticamente accettabili
CA2060333A1 (en) Use of pyrimido-benzothiazine derivatives
DE69434010D1 (de) C7-Taxan-Derivate und diese enthaltende pharmazeutische Zusammenstellungen

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970530